JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Russell MD, Stovin C, Alveyn E, Adeyemi O, et al. Ann Rheum Dis 2023;82:1059-1067.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Russell MD, Stovin C, Alveyn E, Adeyemi O, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis 2023;82:1059-1067.
PMID: 37247942